Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023

Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC):Developing new treatment options for people with blood cancersExtended follow-up data for Columvi ® (glofitamab) of almost two years (20 months) from the pivotal phase II NP30179 study, further investigating the potential of fixed-duration Columvi to provide durable responses in people with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)Early data from the phase Ib NP40126 study of Columvi in combination with Polivy plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) in previously untreated DLBCL. These data support Roche ’s overall goal to develop combination treatments with Polivy® (polatuzumab vedotin) and its CD20xCD3 bispecific antibodies, Lunsumio® (mosunetuzumab) and Columvi (glofitamab) to optimise patient outcomesSubgroup analysis data from the phase III POLARIX trial of Polivy in combination with R-CHP in elderly patients with previously untreated DLBCLBuilding on progress in treating liver cancerAnalysis of patient-reported outcomes (PROs) from IMbrave050 in adjuvant hepatocellular carcinoma (HCC), including quality of life data. These data are intended to provide a more comprehensive evaluation o...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news